Catalyst Funds Management Pty Ltd Invests $31,000 in Orchestra BioMed Holdings, Inc. $OBIO

Catalyst Funds Management Pty Ltd purchased a new stake in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,400 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in shares of Orchestra BioMed by 67.3% in the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company’s stock valued at $87,000 after buying an additional 8,134 shares in the last quarter. Knott David M Jr acquired a new stake in Orchestra BioMed during the 2nd quarter worth $268,000. Y Intercept Hong Kong Ltd purchased a new stake in Orchestra BioMed in the second quarter valued at $122,000. Nuveen LLC acquired a new position in Orchestra BioMed in the first quarter valued at $179,000. Finally, Bank of America Corp DE grew its holdings in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after purchasing an additional 7,036 shares during the last quarter. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Price Performance

Orchestra BioMed stock opened at $4.53 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. The stock has a market capitalization of $255.81 million, a PE ratio of -2.49 and a beta of 0.65. The business has a 50 day simple moving average of $3.39 and a 200-day simple moving average of $3.06. Orchestra BioMed Holdings, Inc. has a 12 month low of $2.20 and a 12 month high of $6.30.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%. Equities analysts predict that Orchestra BioMed Holdings, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on OBIO shares. BTIG Research reissued a “neutral” rating on shares of Orchestra BioMed in a report on Wednesday, August 20th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Thursday, November 13th. HC Wainwright reduced their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, September 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. Finally, Barclays cut their target price on shares of Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Orchestra BioMed Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.